Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in Adult Patients With Systemic Sclerosis
NCT07047690Phase 2Recruiting
- Sponsor
- Galderma
- Start
- Feb 2026
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nemolizumab in systemic sclerosis (SSc), sponsored by Galderma. Started Feb 2026; status: recruiting.
02
Drugs
nemolizumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07047690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07047690.